EXPRS2 Stock Overview
Through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.86 |
52 Week High | SEK 5.80 |
52 Week Low | SEK 0.71 |
Beta | 1.68 |
11 Month Change | -22.94% |
3 Month Change | -42.05% |
1 Year Change | -72.30% |
33 Year Change | -98.58% |
5 Year Change | -82.08% |
Change since IPO | -84.78% |
Recent News & Updates
Shareholder Returns
EXPRS2 | SE Biotechs | SE Market | |
---|---|---|---|
7D | -0.6% | -2.4% | -4.3% |
1Y | -72.3% | 18.0% | 12.6% |
Return vs Industry: EXPRS2 underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: EXPRS2 underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
EXPRS2 volatility | |
---|---|
EXPRS2 Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: EXPRS2's share price has been volatile over the past 3 months.
Volatility Over Time: EXPRS2's weekly volatility has decreased from 35% to 11% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 18 | Bent Frandsen | www.expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
EXPRS2 fundamental statistics | |
---|---|
Market cap | SEK 71.92m |
Earnings (TTM) | -SEK 77.95m |
Revenue (TTM) | SEK 7.77m |
9.3x
P/S Ratio-0.9x
P/E RatioIs EXPRS2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EXPRS2 income statement (TTM) | |
---|---|
Revenue | SEK 7.77m |
Cost of Revenue | SEK 3.32m |
Gross Profit | SEK 4.44m |
Other Expenses | SEK 82.39m |
Earnings | -SEK 77.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
Earnings per share (EPS) | -0.93 |
Gross Margin | 57.22% |
Net Profit Margin | -1,003.55% |
Debt/Equity Ratio | 0.6% |
How did EXPRS2 perform over the long term?
See historical performance and comparison